Artivion (NYSE:AORT) Price Target Cut to $32.00 by Analysts at Needham & Company LLC

Artivion (NYSE:AORT) had its target price decreased by investment analysts at Needham & Company LLC from $34.00 to $32.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 14.70% from the stock’s previous close.

Several other brokerages also recently commented on AORT. Oppenheimer increased their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Trading Down 1.3 %

AORT opened at $27.90 on Tuesday. The business has a 50 day simple moving average of $29.75 and a two-hundred day simple moving average of $27.83. Artivion has a one year low of $18.38 and a one year high of $32.33. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -1,394.90 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Insiders Place Their Bets

In related news, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares of the company’s stock, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last three months. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its position in Artivion by 30.8% during the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after purchasing an additional 8,404 shares in the last quarter. Tidal Investments LLC lifted its position in shares of Artivion by 14.5% during the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock valued at $5,141,000 after buying an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the 4th quarter valued at about $64,000. Point72 Asset Management L.P. purchased a new position in shares of Artivion in the 4th quarter worth approximately $5,573,000. Finally, ProShare Advisors LLC raised its stake in shares of Artivion by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after acquiring an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.